

## UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Vignia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.	
09/926,330	12/07/2001	Estelle Bonnin	214896US0PCT	6480	
22850	7590 09/15/2003				
	OBLON, SPIVAK, MCCLELLAND, MAIER & NEUSTADT, P.C.			EXAMINER	
	1940 DUKE STREET ALEXANDRIA, VA 22314		MARX, IRENE		
			ART UNIT	PAPER NUMBER	
			1651		
			DATE MAILED: 09/15/2003		

Please find below and/or attached an Office communication concerning this application or proceeding.

	Application No.	Applicant(s)			
	09/926,330	BONNIN ET AL.			
Office Action Summary	Examiner	Art Unit			
	Irene Marx	1651			
The MAILING DATE of this communication ap	pears on the cover sheet wit	th the correspondence address			
Period for Reply	VIC OFT TO EVOIDE AND	ONTU(O) EDOM			
A SHORTENED STATUTORY PERIOD FOR REPL THE MAILING DATE OF THIS COMMUNICATION.  - Extensions of time may be available under the provisions of 37 CFR 1. after SIX (6) MONTHS from the mailing date of this communication.  - If the period for reply specified above is less than thirty (30) days, a rep If NO period for reply is specified above, the maximum statutory period Failure to reply within the set or extended period for reply will, by statut Any reply received by the Office later than three months after the mailir earned patent term adjustment. See 37 CFR 1.704(b).  Status	136(a). In no event, however, may a re oly within the statutory minimum of thirty I will apply and will expire SIX (6) MONT te, cause the application to become ABA	uply be timely filed  r (30) days will be considered timely.  THS from the mailing date of this communication.  ANDONED (35 U.S.C. § 133).			
1) Responsive to communication(s) filed on 14	<u>August 2003</u> .				
2a) ☐ This action is <b>FINAL</b> . 2b) ☑ TI	his action is non-final.				
Since this application is in condition for allow closed in accordance with the practice under Disposition of Claims					
4) Claim(s) 1-11 is/are pending in the application	n				
4a) Of the above claim(s) <u>5-11</u> is/are withdraw					
5) Claim(s) is/are allowed.					
6) Claim(s) <u>1-4</u> is/are rejected.					
7) Claim(s) is/are objected to.					
8) Claim(s) are subject to restriction and/o	or election requirement.				
Application Papers	·				
9)☐ The specification is objected to by the Examine	er.				
10)☐ The drawing(s) filed on is/are: a)☐ acce	epted or b) objected to by th	e Examiner.			
Applicant may not request that any objection to the	ne drawing(s) be held in abeya	nce. See 37 CFR 1.85(a).			
11) The proposed drawing correction filed on	_ is: a)∏ approved b)∏ di	sapproved by the Examiner.			
If approved, corrected drawings are required in re	eply to this Office action.				
12) The oath or declaration is objected to by the Ex	xaminer.				
Priority under 35 U.S.C. §§ 119 and 120					
13) Acknowledgment is made of a claim for foreig	n priority under 35 U.S.C. §	119(a)-(d) or (f).			
a) ☐ All b) ☐ Some * c) ☐ None of:					
1. Certified copies of the priority document	ts have been received.				
2. Certified copies of the priority document	ts have been received in Ap	pplication No			
<ul> <li>3. Copies of the certified copies of the price</li> <li>application from the International But</li> <li>* See the attached detailed Office action for a list</li> </ul>	ureau (PCT Rule 17.2(a)).	•			
14) Acknowledgment is made of a claim for domest	tic priority under 35 U.S.C. §	119(e) (to a provisional application).			
a) The translation of the foreign language pro	ovisional application has be	en received.			
Attachment(s)	•				
1) Notice of References Cited (PTO-892) 2) Notice of Draftsperson's Patent Drawing Review (PTO-948) 3) Information Disclosure Statement(s) (PTO-1449) Paper No(s)	5) Notice of In	ummary (PTO-413) Paper No(s) formal Patent Application (PTO-152)			

Art Unit: 1651

The application should be reviewed for errors and conformity with domestic practice. Applicant's election with traverse of Group I, claims 1-4 is acknowledged.

The traversal is on the ground(s) that the Office has mischaracterized the invention of Group I to be drawn to a process of making "strains" of *Aspergillus niger* as opposed to "cultures" thereof having a broad spectrum of enzymatic activity. However, the "cultures" are produced by culturing "at least one *Aspergillus niger* strain" and the product produced by a "strain" or a "culture" is the same. These terms are often used interchangeably. The product produced is not specified with any particularity, except in claim 4, wherein a culture supernatant is recovered.

Contrary to applicant's argument regarding the Kroon reference, any enzymatic preparation meets the requirements of claim 5. It is noted that this product is merely "an enzymatic preparation". That it "can be produced" by the method of claim 4 does not confer any particular properties on the composition.

Applicant also argues that because the same standard of unity of invention was not applied as in the International Preliminary Examination authority, the restriction is improper. That no objection to unity of invention was raised in the searching process in the PCT prosecution is not binding in the present case.

The claims as written are drawn to several inventions which are not linked by a special technical feature to form a single general inventive concept as is required for unity of invention.

Burden of examination is not an issue in requirements due to lack of unity of invention.

For the reasons outlined, the arguments are not persuasive of error in the lack of unity requirement made.

Clearly different searches and issues are involved with each group.

For these reasons, the restriction requirement is deemed proper and is adhered to. The restriction requirement is hereby made FINAL.

Claims 3 and 4 objected to under 37 CFR 1.75(c) as being in improper form because a multiple dependent claim may not depend on another multiple dependent claim and because the claims must be dependent in the alternative. In claim 3, "either... and" is not clearly in the alternative. See MPEP § 608.01(n).

Art Unit: 1651

## Claim Rejections - 35 USC § 112

The following is a quotation of the second paragraph of 35 U.S.C. 112:

The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.

Claims 1-4 re rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.

A broad range or limitation together with a narrow range or limitation that falls within the broad range or limitation (in the same claim) is considered indefinite, since the resulting claim does not clearly set forth the metes and bounds of the patent protection desired. Note the explanation given by the Board of Patent Appeals and Interferences in *Ex parte Wu*, 10 USPQ2d 2031, 2033 (Bd. Pat. App. & Inter. 1989), as to where broad language is followed by "such as" and then narrow language. The Board stated that this can render a claim indefinite by raising a question or doubt as to whether the feature introduced by such language is (a) merely exemplary of the remainder of the claim, and therefore not required, or (b) a required feature of the claims. Note also, for example, the decisions of *Ex parte Steigewald*, 131 USPQ 74 (Bd. App. 1961); *Ex parte Hall*, 83 USPQ 38 (Bd. App. 1948); and *Ex parte Hasche*, 86 USPQ 481 (Bd. App. 1949). In the present instance, claim 1 recites the broad recitation "a cereal bran", and the claims also recite "in particular a maize bran" which is the narrower statement of the range/limitation; claim 2 recites the broad recitation of g/L followed by the narrower, "preferably".

Claims 1-4 are confusing, vague and indefinite in the recitation of "in the presence of" at least one inducing carbon-containing source chosen...", since it is doubted that the mere "presence" of such a substance is sufficient. In addition, it is unclear what constitutes "inducing carbon-containing source" in this context, since it is unclear what is induced by this presence.

Claim 1 is vague, indefinite and confusing in the recitation of "comprising enzymes which degrade the parietal polysaccharides and ferulate esterases". It is at least ambiguous whether ferulate esterases are produced or degraded. The claim is further confusing in that the nature of "the parietal polysaccharides" intended is uncertain. The phrase lacks internal

Application/Control Number: 09/926,330 Page 4

Art Unit: 1651

antecedent basis. The intended enzymatic activity cannot be determined with any particularity.

The claims are vague and indefinite in the recitation of "is characterized in that", because it is unclear which characteristics are or are not encompassed. It is suggested that --wherein-- be replaced therefor.

Claims 1-3 are incomplete in the absence of a recovery step for the product produced.

While there is no specific rule or statutory requirement which specifically addresses the need for a recovery step in a process of preparing a composition, it is clear from the record and would be expected from conventional preparation processes that the product must be isolated or recovered. Thus, the claims fail to particularly point out and distinctly claim the "complete" process since the recovery step is missing from the claims. The metes and bounds of the claimed process are therefore not clearly established or delineated.

## Rejections under 35 U.S.C § 112

The following is a quotation of the first paragraph of 35 U.S.C. 112:

The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

Claim 3 is rejected under 35 U.S.C. 112, first paragraph, as containing subject matter which was not described in the specification in such a way as to enable one skilled in the art to which it pertains, or with which it is most nearly connected, to make and/or use the invention.

The invention appears to employ novel strain of *Aspergillus niger*. It is not clear if the written description is sufficiently repeatable to avoid the need for a deposit. Further it is unclear if the starting materials were readily available to the public at the time of invention.

It appears that a deposit was made in this application as filed as noted on page 4 of the specification. However, it is not clear if the deposit meets all of the criteria set forth in 37 CFR 1.801-1.809. Applicant or applicant's representative may provide assurance of compliance with the requirements of 35 U.S.C § 112, first paragraph, in the following manner.

SUGGESTION FOR DEPOSIT OF BIOLOGICAL MATERIAL

A declaration by applicant, assignee, or applicant's agent identifying a deposit of biological material and averring the following may be sufficient to overcome an objection and rejection based on a lack of availability of biological material.

## 1. Identifies declarant.

Art Unit: 1651

2. States that a deposit of the material has been made in a depository affording permanence of the deposit and ready accessibility thereto by the public if a patent is granted. The depository is to be identified by name and address.

- 3. States that the deposited material has been accorded a specific (recited) accession number.
- 4. States that all restriction on the availability to the public of the material so deposited will be irrevocably removed upon the granting of a patent.
- 5. States that the material has been deposited under conditions that access to the material will be available during the pendency of the patent application to one determined by the Commissioner to be entitled thereto under 37 CFR 1.14 and 35 U.S.C § 122.
- 6. States that the deposited material will be maintained with all the care necessary to keep it viable and uncontaminated for a period of at least five years after the most recent request for the furnishing of a sample of the deposited microorganism, and in any case, for a period of at least thirty (30) years after the date of deposit for the enforceable life of the patent, whichever period is longer.
- 7. That he/she declares further that all statements made therein of his/her own knowledge are true and that all statements made on information and belief are believed to be true, and further that these statements were made with knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the instant patent application or any patent issuing thereon.

Alternatively, it may be averred that deposited material has been accepted for deposit under the Budapest Treaty on the International Recognition of the Deposit of Microorganisms for the purpose of Patent Procedure (e.g. see 961 OG 21, 1977) and that all restrictions on the availability to the public of the material so deposited will be irrevocably removed upon the granting of a patent.

Additionally, the deposit must be referred to in the body of the specification and be identified by deposit (accession) number, date of deposit, name and address of the depository and the complete taxonomic description.

The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless -

Art Unit: 1651

(b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made.

This application currently names joint inventors. In considering patentability of the claims under 35 U.S.C. 103(a), the examiner presumes that the subject matter of the various claims was commonly owned at the time any inventions covered therein were made absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and invention dates of each claim that was not commonly owned at the time a later invention was made in order for the examiner to consider the applicability of 35 U.S.C. 103(c) and potential 35 U.S.C. 102(e), (f) or (g) prior art under 35 U.S.C. 103(a).

Claims 1-4 are rejected under 35 U.S.C. 102(b) as being anticipated by Kroon *et al.*(I)((1996) Biotechnol. Appl. Biochem. vol. 23, pages 255-262)

The reference teaches a process of producing Aspergillus niger cultures by culturing at least one Aspergillus niger strain in the presence of sugar-beet pulp in the required amount. The culture supernatant or filtrate is recovered. See, e.g., page 256, paragraph 2. This material clearly has broad enzymatic activity that comprises various enzymes having degradative ability, including at least two esterases and including at least one ferulate esterase. Moreover, the culture medium produced by any one strain or by a mixture of strains naturally contains mixtures of enzymes having a broad spectrum of activity including enzymes which degrade polysaccharides, lipids, esters, proteins, etc., since various enzymes are naturally produced and are required to effect their metabolic activities.

The addition in claim 3 of a specific strain in the culturing process does not appear to materially affect the process.

Therefore, the claims are deemed to be anticipated by the reference.

No claim is allowed.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Irene Marx whose telephone number is 703-308-2922. The examiner can normally be reached on M-F (6:30-3:00).

Art Unit: 1651

Page 7

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Michael G. Wityshyn can be reached on 703-308-4743. The fax phone number for the organization where this application or proceeding is assigned is (703) 872-9306.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is 703-308-0926.

Irene Marx
Primary Examiner
Art Unit 1651